Loading clinical trials...

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON) | Clinical Trials | Clareo Health

RECRUITINGPHASE2

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

NCT06978725•Priovant Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults subjects (18-74)
•2. Cutaneous sarcoidosis with characteristic skin biopsy histology
•3. A CSAMI activity score ≥ 10
•4. Weight \> 40 kg to \< 130 kg with BMI \< 40 kg/m2 .

Exclusion Criteria

•1. History of
•* Lymphoproliferative disorder
•* Active malignancy;
•* History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
•2. High risk of thrombosis or cardiovascular disease
•3. High risk of herpes zoster
•4. Active or recent infection

Locations (4)

Clinical Trial Site

San Francisco, California, United States

Clinical Trial Site

Durham, North Carolina, United States

Clinical Trial Site

Philadelphia, Pennsylvania, United States

Clinical Trial Site

Madison, Wisconsin, United States

Key Dates

Start Date

April 9, 2025

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

May 18, 2025

Enrollment

ESTIMATED participants

Conditions

Cutaneous Sarcoidosis

Interventions

Oral Brepocitinib

DRUG

Oral Placebo

DRUG

Contacts

Clinical Trial Administrator

CONTACT

(212) 634-9743 clinicaltrials@priovant.com

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

NCT03910543

Cutaneous SarcoidosisGranuloma Annulare

View study

COMPLETEDPHASE2/PHASE3

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274

SarcoidosisCutaneous Sarcoidosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions